Dr. Wiland, et al, reply

Affiliations

¹ Head of Department, Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland; pwiland1@gmail.com.
² Clinic of Rheumatology, HFR Fribourg, Hôpital Cantonal, Fribourg, Switzerland.
³ Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland.
⁴ Barts Health National Health Service Trust, London, UK.
⁵ Pfizer Inc.
⁶ Pfizer Inc., Collegeville, Pennsylvania, USA.

Comment

Piotr Wiland et al. J Rheumatol. 2017 Feb.

. 2017 Feb;44(2):259.

doi: 10.3899/jrheum.161405.

¹ Head of Department, Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland; pwiland1@gmail.com.
² Clinic of Rheumatology, HFR Fribourg, Hôpital Cantonal, Fribourg, Switzerland.
³ Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland.
⁴ Barts Health National Health Service Trust, London, UK.
⁵ Pfizer Inc.
⁶ Pfizer Inc., Collegeville, Pennsylvania, USA.

No abstract available

Comment on

The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, Vlahos B, Williams T, Gaylord S, Kotak S. Wiland P, et al. J Rheumatol. 2016 Jul;43(7):1268-77. doi: 10.3899/jrheum.151179. Epub 2016 Jun 1. J Rheumatol. 2016. PMID: 27252426 Clinical Trial.
Patients with Rheumatoid Arthritis in Remission While Receiving Etanercept Plus Methotrexate Therapy May Require Adjustment of Dosing Regimen When Switched to Methotrexate Monotherapy.
Bannwarth B. Bannwarth B. J Rheumatol. 2017 Feb;44(2):259. doi: 10.3899/jrheum.160815. J Rheumatol. 2017. PMID: 28148757 No abstract available.